Literature DB >> 20207476

A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.

Hao Liu1, Anmin Chen, Fengjing Guo, Lin Yuan.   

Abstract

Osteopontin (OPN), a secreted phosphoglycoprotein, is frequently associated with cell proliferation and tumor metastatic spread in a variety of cancers. It has been reported that OPN induce matrix metalloproteinase (MMP)-2 and MMP-9 activations through nuclear factor kappaB (NF-kappaB)-mediated signaling pathways. In this study, we investigated the roles of OPN in human prostate cancer cells and provided clues about the possible functions of IkappaB kinase (IKK) in NF-kappaB-mediated OPN-induced activations of MMP-2 and MMP-9. Short-hairpin RNA (shRNA) expression vectors were used to inhibit OPN expression in PC-3 cells, human prostate cancer cell line, and IKK inhibitor VII were applied to inhibit the activities of IKK-1 and IKK-2. The results showed that OPN shRNA-mediated RNA interference can downregulate OPN, MMP-2 and MMP-9 expressions, thereby resulting in suppression of the proliferation, migration and invasion of PC-3 cells in vitro and tumor growth in vivo. Moreover, the inhibition of IKK-2 can suppress MMP-2 and MMP-9 expressions, in contrast, the inhibition of IKK-1 has no effects on the OPN, MMP-2 and MMP-9 expression levels. Thus, this study demonstrated that OPN knockdown could downregulate MMP-2 and MMP-9 expressions result in inhibiting the malignant physiological behaviors of PC-3 cell and that IKK-2 may play a crucial role in OPN-induced MMP-2 and MMP-9 expressions via NF-kappaB-mediated signaling pathways. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20207476     DOI: 10.1016/j.canlet.2010.02.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

Review 2.  Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells.

Authors:  Amy L Strong; Matthew E Burow; Jeffrey M Gimble; Bruce A Bunnell
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

3.  Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma.

Authors:  Maryam Mardani; Azadeh Andisheh-Tadbir; Bijan Khademi; Mohammad Javad Fattahi; Shapour Shafiee; Maryam Asad-Zadeh
Journal:  Tumour Biol       Date:  2013-12-14

4.  The potential of osteopontin as a therapeutic target for human colorectal cancer.

Authors:  Wang Likui; Wang Hong; Zhang Shuwen; You Yuangang; Wen Yan
Journal:  J Gastrointest Surg       Date:  2011-02-12       Impact factor: 3.452

5.  Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells.

Authors:  Xin-Lin Wu; Kai-Jin Lin; Ai-Ping Bai; Wan-Xiang Wang; Xing-Kai Meng; Xiu-Lan Su; Ming-Xing Hou; Pei-De Dong; Jun-Jing Zhang; Zhao-Yang Wang; Lin Shi
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

6.  Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells.

Authors:  Melissa Lazar; Jennifer Sullivan; Galina Chipitsyna; Qiaoke Gong; Chee Y Ng; Ahmed F Salem; Tamer Aziz; Agnes Witkiewicz; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

7.  Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis.

Authors:  Sheng-Zhang Lin; Wei-Tian Wei; Hui Chen; Kang-Jie Chen; Hong-Fei Tong; Zhao-Hong Wang; Zhong-Lin Ni; Hai-Bin Liu; Hong-Chun Guo; Dian-Lei Liu
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

8.  A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro.

Authors:  Jiang Wang; Anmin Chen; Caihong Yang; Heng Zeng; Jun Qi; Feng-Jin Guo
Journal:  Oncol Rep       Date:  2011-11-30       Impact factor: 3.906

9.  Anti-tumor effects of Mfn2 in gastric cancer.

Authors:  Ge-Er Zhang; Hai-Long Jin; Xian-Ke Lin; Chao Chen; Xiao-Sun Liu; Qing Zhang; Ji-Ren Yu
Journal:  Int J Mol Sci       Date:  2013-06-24       Impact factor: 5.923

10.  Gene set signature of reversal reaction type I in leprosy patients.

Authors:  Marianna Orlova; Aurélie Cobat; Nguyen Thu Huong; Nguyen Ngoc Ba; Nguyen Van Thuc; John Spencer; Yohann Nédélec; Luis Barreiro; Vu Hong Thai; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  PLoS Genet       Date:  2013-07-11       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.